Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  White, Robert E ^a   Groves, Ian J ^a   Turro, Ernest ^a   Yee, Jade ^a   Kremmer, Elisabeth ^b   Allday, Martin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 3A; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 3B; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; EBNA 3A ANTIGEN; EBNA 3B ANTIGEN; EBNA 3C, EPSTEIN BARR VIRUS; EBNA-3A ANTIGEN; EBNA-3B ANTIGEN; EBNA-3C, EPSTEIN-BARR VIRUS; VIRUS ANTIGEN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFORMATION; MICROARRAY ANALYSIS; MITOSIS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VIRUS CELL INTERACTION; CELL STRAIN HEK293; CHROMATIN; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

HUMAN HERPESVIRUS 4;

ANTIGENS, VIRAL; CELL LINE, TUMOR; CHROMATIN; CLUSTER ANALYSIS; EPIGENOMICS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649746843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013979     Document Type: Article

References (83)

1. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
2. Swaminathan S (2008) Noncoding RNAs produced by oncogenic human herpesviruses. Journal of Cellular Physiology 216: 321-326.
3. Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond, B, Biol Sci 356: 461-473.
4. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. The New England Journal of Medicine 350: 1328-1337.
5. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6: 913-924.
6. Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol 83: 3968-3976.
7. Touitou R, O'Nions J, Heaney J, Allday MJ (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86: 1269-1277.
8. Tomkinson B, Robertson E, Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014-2025.
9. Young LS, Murray PG (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121.
10. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
11. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic Repression of p16INK4A by Latent Epstein-Barr Virus Requires the Interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
12. Tomkinson B, Kieff E (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66: 2893-2903.
13. Chen A, Divisconte M, Jiang X, Quink C, Wang F (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79: 4506-4509.
14. Henkel T, Ling PD, Hayward SD, Peterson MG (1994) Mediation of Epstein- Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265: 92-95.
15. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M (1994) The Epstein- Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA- 2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205: 596-602.
16. Waltzer L, Perricaudet M, Sergeant A, Manet E (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70: 5909-5915.
17. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, et al. (1997) Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71: 8552-8562.
18. Cludts I, Farrell PJ (1998) Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol 72: 1862-1869.
19. Zimber-Strobl U, Strobl LJ (2001) EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 11: 423-434.
20. Bourillot PY, Waltzer L, Sergeant A, Manet E (1998) Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa. J Gen Virol 79(Pt 2): 363-370.
21. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277: 47197-47204.
22. Bain M, Watson RJ, Farrell PJ, Allday MJ (1996) Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol 70: 2481-2489.
23. Radkov SA, Touitou R, Brehm A, Rowe M, West M, et al. (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73: 5688-5697.
24. Knight JS, Lan K, Subramanian C, Robertson ES (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261-4272.
25. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749-7755.
26. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
27. Simon JA, Kingston RE (2009) Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10: 697-708.
28. O'Nions J, Allday MJ (2004) Deregulation of the cell cycle by the Epstein-Barr virus. Adv Cancer Res 92: 119-186.
29. Kamranvar SA, Gruhne B, Szeles A, Masucci MG (2007) Epstein-Barr viruspromotes genomic instability in Burkitt's lymphoma. Oncogene 26: 5115-5123.
30. Gruhne B, Sompallae R, Masucci M (2009) Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 28: 3997-4008.
31. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, et al. (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13: 2541-2549.
32. Parker GA, Touitou R, Allday MJ (2000) Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19: 700-709.
33. Knight JS, Robertson ES (2004) Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78: 1981-1991.
34. Knight JS, Sharma N, Robertson ES (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America 102: 18562-18566.
35. Knight JS, Sharma N, Robertson ES (2005) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25: 1749-1763.
36. Knight JS, Sharma N, Kalman DE, Robertson ES (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. Journal of Virology 78: 12857-12867.
37. Yi F, Saha A, Murakami M, Kumar P, Knight JS, et al. (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236-247.
38. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. Journal of Virology 83: 4652-4669.
39. Calderwood MA, Johannsen E (2010) Molecular Profiles of EBV Latently Infected Cells (Chapter 6 in: Epstein-barr Virus: Latency and Transformation; ed E. Robertson). 220 p.
40. Chen A, Zhao B, Kieff E, Aster JC, Wang F (2006) EBNA-3B- and EBNA-3Cregulatedcellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 80: 10139-10150.
41. Young P, Anderton E, Paschos K, White R, Allday MJ (2008) Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones. J Gen Virol 89: 866-877.
42. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421-433.
43. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743-2751.
44. Murray RJ, Young LS, Calender A, Gregory CD, Rowe M, et al. (1988) Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains. J Virol 62: 894-901.
45. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 95: 8245-8250.
46. Turro E, Lewin A, Rose A, Dallman MJ, Richardson S (2010) MMBGX: a method for estimating expression at the isoform level and detecting differential splicing using whole-transcript Affymetrix arrays. Nucleic Acids Research 38: e4.
47. Northrup DL, Allman D (2008) Transcriptional regulation of early B cell development. Immunol Res 42: 106-117.
48. Schmidlin H, Diehl S, Blom B (2009) New insights into the regulation of human B-cell differentiation. Trends in immunology 30: 277-285.
49. Pillai S, Cariappa A (2009) The follicular versus marginal zone B lymphocyte cell fate decision. Nature Reviews Immunology 9: 767-777.
50. Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad J, et al. (2003) Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 100: 2639-2644.
51. Lee J-E, Nam H-Y, Shim S-M, Bae G-R, Han B-G, et al. (2010) Expression phenotype changes of EBV-transformed lymphoblastoid cell lines during long-term subculture and its clinical significance. Cell Prolif 43: 378-384.
52. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, et al. (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol 87: 2859-2867.
53. Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, et al. (2008) Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. Journal of Virology 82: 7456-7466.
54. Maier S, Staffler G, Hartmann A, Höck J, Henning K, et al. (2006) Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 80: 9761-9771.
55. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci USA 103: 19500-19505.
56. Burgess A, Buck M, Krauer K, Sculley T (2006) Nuclear localization of the Epstein-Barr virus EBNA3B protein. J Gen Virol 87: 789-793.
57. Krauer KG, Buck M, Belzer DK, Flanagan J, Chojnowski GM, et al. (2004) The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein. Virology 318: 280-294.
58. Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, et al. (2007) Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci USA 104: 7606-7611.
59. Bracken AP, Helin K (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9: 773-784.
60. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. (2006) Aivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326.
61. Ochiai K, Muto A, Tanaka H, Takahashi S, Igarashi K (2008) Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol 20: 453-460.
62. Baik SY, Yun HS, Lee HJ, Lee MH, Jung SE, et al. (2007) Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes. Cell Prolif 40: 268-281.
63. Wade M, Allday MJ (2000) Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 20: 1344-1360.
64. Lee S, Sakakibara S, Maruo S, Zhao B, Calderwood MA, et al. (2009) Epstein- Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol 83: 12368-12377.
65. Sugimoto M, Tahara H, Ide T, Furuichi Y (2004) Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 64: 3361-3364.
66. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S (1995) Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85: 2315-2320.
67. Yang J, Deng X, Deng L, Gu H, Fan W, et al. (2004) Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res 23: 495-506.
68. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, et al. (2008) The Latent Membrane Protein-1 of Epstein-Barr virus activates hTERT promoter and enhances telomerase activity in B lymphocytes. Journal of Virology.
69. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21: 220-224.
70. Scheeren FA, Nagasawa M, Weijer K, Cupedo T, Kirberg J, et al. (2008) T cellindependent development and induction of somatic hypermutation in human IgM+ IgD+ CD27+ B cells. J Exp Med 205: 2033-2042.
71. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2007) Influence of EBV on the peripheral blood memory B cell compartment. J Immunol 179: 3153-3160.
72. Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, et al. (2009) Evolutionarily conserved herpesviral protein interaction networks. PLoS Pathog 5: e1000570.
73. Ling PD, Peng RS, Nakajima A, Yu JH, Tan J, et al. (2005) Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J 24: 3565-3575.
74. Nitsche F, Bell A, Rickinson A (1997) Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol 71: 6619-6628.
75. Harada S, Kieff E (1997) Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 71: 6611-6618.
76. Allan GJ, Rowe DT (1989) Size and stability of the Epstein-Barr virus major internal repeat (IR-1) in Burkitt's lymphoma and lymphoblastoid cell lines. Virology 173: 489-498.
77. Marshall D, Sample C (1995) Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol 69: 3624-3630.
78. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, et al. (1995) Epstein- Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69: 3108-3116.
79. White RE, Calderwood MA, Whitehouse A (2003) Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demon strates that the terminal repeats are required for both virus production and episomal persistence. J Gen Virol 84: 3393-3403.
80. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ (2002) Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci USA 99: 15036-15041.
81. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, et al. (1987) Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A 84: 8060-8064.
82. Finke J, Rowe M, Kallin B, Ernberg I, Rosén A, et al. (1987) Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. Journal of Virology 61: 3870-3878.
83. Kremmer E, Kranz BR, Hille A, Klein K, Eulitz M, et al. (1995) Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). Virology 208: 336-342.